P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics

Ähnliche Einträge

• Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
  von: Bhayat, F, et al.
  Veröffentlicht: (2017)
• Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
  von: Bhayat, F, et al.
  Veröffentlicht: (2017)
• Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
  von: Travis, S, et al.
  Veröffentlicht: (2018)
• The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data
  von: Cohen, R, et al.
  Veröffentlicht: (2019)
• Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
  von: Card, T, et al.
  Veröffentlicht: (2019)